-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $149

Benzinga·11/06/2026 15:21:25
Listen to the news
Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $93 to $149.